Journal
BMJ CASE REPORTS
Volume 14, Issue 10, Pages -Publisher
BMJ PUBLISHING GROUP
DOI: 10.1136/bcr-2021-246580
Keywords
Heart failure; COVID-19; Drug interactions; Global Health; Vaccination; immunisation
Categories
Ask authors/readers for more resources
Community vaccination is the primary strategy to control the global COVID-19 pandemic, but potential vaccine-related adverse events should be carefully considered.
The global COVID-19 pandemic remains challenging with efforts for community vaccination the primary strategy to control transmission and disease sequalae in the mid to long term. While several candidate vaccines have been approved for use, there is an ongoing discussion regarding potential vaccine-related adverse events. Notably, thrombotic thrombocytopaenia has been reported following ChAdOx1 nCov-19 (AstraZeneca) vaccination. We report the first known case of takotsubo (stress) cardiomyopathy 4 days after administration of the ChAdOx1 nCoV-19 vaccine in a 72-year-old man. While this condition remains one primarily seen in females, our case represents a new trigger that warrants careful consideration when assessing patients presenting with acute coronary syndromes following ChAdOx1 nCoV-19 vaccination.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available